Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

COPD immune mystery: scientists probe why lungs can't clear bacteria.

NCT ID NCT05743582

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at why immune cells in people with COPD don't work properly to clear bacteria from the lungs. Researchers will collect cells from the lungs and blood of 189 participants, including COPD patients and healthy smokers and non-smokers. They will study how these cells use energy and respond to bacteria, aiming to find new ways to treat COPD in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could point toward new treatments for COPD by targeting immune cell metabolism.
What could go wrong
This is an observational study, not a treatment trial. It is early-stage research, and findings may not lead to therapies for years, if at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 189 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2023

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

189 participants split evenly into: COPD patients, healthy smokers, healthy non-smokers (63 each)

Ages

18 to 77 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: COPD patients: * COPD patients aged 18-77 years who are GOLD Stage 1 or 2 or 3; for patients undergoing bronchoscopy already for a clinical reason. * COPD patients aged 18-77 years old who are GOLD Stage 1,2 or 3 for patients who are donating blood only. * COPD patients aged 18-69 years who are GOLD Stage 1 or 2 for patients undergoing bronchoscopy for research purposes. * COPD- Defined by radiological investigation of chest either chest X-ray or High-resolution CT scan in previous 12 months * Ability to provide informed consent Healthy volunteers: * Any healthy volunteer aged 18-77 years * Ability to provide informed consent Exclusion Criteria: COPD patients: * Individuals known to have active malignancy, immunosuppression, diabetes mellitus, chronic kidney disease or hepatic failure. * Individuals with a history of anaemia * Individuals who have donated \>250 ml of blood for any reason within the last 6 months * Individuals who are pregnant or breast feeding. * Current participation in any other clinical trial, except those directly relating to this cohort and study. * Individuals who have had a febrile illness or other symptoms of acute infectious illness (respiratory, enteric or soft tissue) within the last 2 weeks * Individuals who have received a vaccine in the past 2 weeks * Inability to communicate in English or convey willingness to participate. * For bronchoscopy - Any significant lung condition that would contra-indicate bronchoscopy including: active acute lung infection (with the exception of asymptomatic pulmonary colonisation) or malignancy, significant coexisting interstitial lung disease or additional pulmonary diagnosis in addition to COPD. Healthy volunteers: * Individuals known to have active malignancy, immunosuppression, diabetes mellitus, chronic kidney disease or hepatic failure * Individuals with anaemia on the screening full blood count (FBC) * Individuals who donated \>250 ml of blood for any reason within the last 6 months * Individuals who are pregnant or breast feeding * Current participation in any other clinical trial * Individuals who have had a febrile illness or other symptoms of acute infectious illness (respiratory, enteric or soft tissue) within the last 2 weeks. * Individuals who have received a vaccine in the past 2 weeks * Chronic or acute respiratory disease. * Any chronic medical condition or receipt of regular prescription medication other than the oral contraceptive pill. * Inability to communicate in English or convey willingness to participate * For bronchoscopy - Any active lung condition including any lung infection or asthma Any significant abnormality on CXR that would contraindicate bronchoscopy FEV1 \<65% predicted (BTS Guidelines, 2001)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Royal Infirmary of Edinburgh

    RECRUITING

    Edinburgh, EH16 5SA, United Kingdom

  • University of Edinburgh

    NOT_YET_RECRUITING

    Edinburgh, EH16 4TJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.